These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771 [No Abstract] [Full Text] [Related]
3. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden. Lee Tokar L; Crotty G; O'Keeffe D; Langabeer SE Blood Cells Mol Dis; 2021 Sep; 90():102593. PubMed ID: 34217938 [No Abstract] [Full Text] [Related]
4. MicroRNAs in myeloid malignancies. Gordon JE; Wong JJ; Rasko JE Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825 [TBL] [Abstract][Full Text] [Related]
5. Sequence conservation of RAG-1 and RAG-2 genes in hematologic malignancies. Mulero MC; Estivill C; Corral J; Sierra J; Baiget M; Nomdedéu JF Leukemia; 2002 Aug; 16(8):1571. PubMed ID: 12145704 [No Abstract] [Full Text] [Related]
6. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Nangalia J; Nice FL; Wedge DC; Godfrey AL; Grinfeld J; Thakker C; Massie CE; Baxter J; Sewell D; Silber Y; Campbell PJ; Green AR Haematologica; 2015 Nov; 100(11):e438-42. PubMed ID: 26250577 [No Abstract] [Full Text] [Related]
7. Notch one up to stroma: endothelial notch prevents inflammation and myeloproliferation. Khalaj M; Park CY Cell Stem Cell; 2014 Jul; 15(1):1-2. PubMed ID: 24996160 [TBL] [Abstract][Full Text] [Related]
8. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. MacGrogan D; Kalakonda N; Alvarez S; Scandura JM; Boccuni P; Johansson B; Nimer SD Genes Chromosomes Cancer; 2004 Nov; 41(3):203-13. PubMed ID: 15334543 [TBL] [Abstract][Full Text] [Related]
9. ZBTB7A links tumor metabolism to myeloid differentiation. Redondo Monte E; Kerbs P; Greif PA Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064 [TBL] [Abstract][Full Text] [Related]
10. Expression and functional significance of osteocalcin splicing in disease progression of hematological malignancies. Wihlidal P; Varga F; Pfeilstöcker M; Karlic H Leuk Res; 2006 Oct; 30(10):1241-8. PubMed ID: 16387359 [TBL] [Abstract][Full Text] [Related]
11. Mutational determinants of epigenetic instablity in myeloid malignancies. Jankowska AM; Szpurka H Semin Oncol; 2012 Feb; 39(1):80-96. PubMed ID: 22289495 [TBL] [Abstract][Full Text] [Related]
12. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Couronné L; Scourzic L; Pilati C; Della Valle V; Duffourd Y; Solary E; Vainchenker W; Merlio JP; Beylot-Barry M; Damm F; Stern MH; Gaulard P; Lamant L; Delabesse E; Merle-Beral H; Nguyen-Khac F; Fontenay M; Tilly H; Bastard C; Zucman-Rossi J; Bernard OA; Mercher T Haematologica; 2013 Nov; 98(11):1748-52. PubMed ID: 23872306 [TBL] [Abstract][Full Text] [Related]
13. Impact of Notch disruption on myeloid development. Francis OL; Chaudhry KK; Lamprecht T; Klco JM Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212 [No Abstract] [Full Text] [Related]
14. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis. Anastasi J Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165 [TBL] [Abstract][Full Text] [Related]